Form 4: AVITA Medical Director Equity Grant Disclosure

Director Robert McNamara received restricted stock units and stock options following shareholder approval.

Summary

• Director Robert McNamara was granted 22,214 restricted stock units (RSUs) and 16,133 stock options.
• The RSU grant vests 12 months after the January 20, 2026, grant date.
• The stock options have an exercise price of $3.77 and expire on January 20, 2036.
• These equity awards were contingent upon shareholder approval, which was officially obtained on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment as it does not impact the company's operational or financial trajectory.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Successful receipt of shareholder approval for the director compensation plan.

Negatives

• Dilutive impact of new equity issuance on existing shareholders.

Risks

• Market price volatility affecting the value of the granted options and RSUs.
• Potential for future dilution if additional equity-based compensation is approved.

Future Outlook

The equity grants are subject to standard time-based vesting, with the RSUs vesting in full on January 20, 2027, and options becoming exercisable on the same date.

Management Comments

• The grants were subject to shareholder approval, which was confirmed on June 3, 2026.

Industry Context

StockSavvy.ai notes that this filing reflects standard corporate governance practices where non-executive director compensation is tied to equity performance, aligning leadership incentives with shareholder outcomes in the medical device sector.

Comparison to Industry Standards

• Equity-based compensation for non-executive directors is a standard practice among mid-cap medical technology companies to attract and retain board talent.
• The use of both RSUs and stock options is consistent with competitive compensation packages in the biotech and medtech industries.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of RSUs on January 20, 2027.
• Options become exercisable on January 20, 2027.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Director Compensation, Equity Grant, Insider Ownership